S&P 500   4,284.63 (-1.22%)
DOW   33,677.40 (-0.97%)
QQQ   355.10 (-1.25%)
AAPL   172.67 (-1.94%)
MSFT   312.10 (-1.71%)
META   299.30 (-0.51%)
GOOGL   127.57 (-2.70%)
AMZN   127.01 (-3.25%)
TSLA   247.43 (+0.18%)
NVDA   423.98 (+0.42%)
NIO   8.55 (+2.40%)
BABA   86.40 (-0.94%)
AMD   96.67 (-0.73%)
T   14.94 (-0.80%)
F   12.52 (-0.48%)
MU   68.62 (+0.06%)
CGC   1.01 (+7.35%)
GE   110.76 (-0.86%)
DIS   80.54 (-0.58%)
AMC   8.28 (+1.72%)
PFE   32.75 (-0.70%)
PYPL   58.89 (+0.05%)
NFLX   383.47 (-0.35%)
S&P 500   4,284.63 (-1.22%)
DOW   33,677.40 (-0.97%)
QQQ   355.10 (-1.25%)
AAPL   172.67 (-1.94%)
MSFT   312.10 (-1.71%)
META   299.30 (-0.51%)
GOOGL   127.57 (-2.70%)
AMZN   127.01 (-3.25%)
TSLA   247.43 (+0.18%)
NVDA   423.98 (+0.42%)
NIO   8.55 (+2.40%)
BABA   86.40 (-0.94%)
AMD   96.67 (-0.73%)
T   14.94 (-0.80%)
F   12.52 (-0.48%)
MU   68.62 (+0.06%)
CGC   1.01 (+7.35%)
GE   110.76 (-0.86%)
DIS   80.54 (-0.58%)
AMC   8.28 (+1.72%)
PFE   32.75 (-0.70%)
PYPL   58.89 (+0.05%)
NFLX   383.47 (-0.35%)
S&P 500   4,284.63 (-1.22%)
DOW   33,677.40 (-0.97%)
QQQ   355.10 (-1.25%)
AAPL   172.67 (-1.94%)
MSFT   312.10 (-1.71%)
META   299.30 (-0.51%)
GOOGL   127.57 (-2.70%)
AMZN   127.01 (-3.25%)
TSLA   247.43 (+0.18%)
NVDA   423.98 (+0.42%)
NIO   8.55 (+2.40%)
BABA   86.40 (-0.94%)
AMD   96.67 (-0.73%)
T   14.94 (-0.80%)
F   12.52 (-0.48%)
MU   68.62 (+0.06%)
CGC   1.01 (+7.35%)
GE   110.76 (-0.86%)
DIS   80.54 (-0.58%)
AMC   8.28 (+1.72%)
PFE   32.75 (-0.70%)
PYPL   58.89 (+0.05%)
NFLX   383.47 (-0.35%)
S&P 500   4,284.63 (-1.22%)
DOW   33,677.40 (-0.97%)
QQQ   355.10 (-1.25%)
AAPL   172.67 (-1.94%)
MSFT   312.10 (-1.71%)
META   299.30 (-0.51%)
GOOGL   127.57 (-2.70%)
AMZN   127.01 (-3.25%)
TSLA   247.43 (+0.18%)
NVDA   423.98 (+0.42%)
NIO   8.55 (+2.40%)
BABA   86.40 (-0.94%)
AMD   96.67 (-0.73%)
T   14.94 (-0.80%)
F   12.52 (-0.48%)
MU   68.62 (+0.06%)
CGC   1.01 (+7.35%)
GE   110.76 (-0.86%)
DIS   80.54 (-0.58%)
AMC   8.28 (+1.72%)
PFE   32.75 (-0.70%)
PYPL   58.89 (+0.05%)
NFLX   383.47 (-0.35%)
LON:COG

Cambridge Cognition (COG) Share Forecast, Price & News

GBX 71.50
-23.30 (-24.58%)
(As of 04:06 PM ET)
Compare
Today's Range
71.50
▼
80
50-Day Range
90.50
▼
98
52-Week Range
71.50
▼
129.74
Volume
855,224 shs
Average Volume
51,127 shs
Market Capitalization
£24.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsInsider TradesHeadlinesOptions Chain

COG stock logo

About Cambridge Cognition (LON:COG) Stock

Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB digital cognitive assessment platform for drug development by enabling pharmaceutical companies to take new therapeutics from preclinical consultancy to pivotal studies and approval, as well as supports sponsors to enhance recruitment, develop safe and effective treatments, and enhance research and development efficiency. It also provides CANTAB Connect Research, a proprietary platform that provides insights into behaviours, underlying brain circuits, and measurement of digital cognitive biomarkers; CANTAB Mobile, a touchscreen assessment of memory, mood, and functional status to detect the earliest signs of clinically relevant memory problems; CANTAB Insight to assess cognitive health; and CANTAB BrainHealth for assessing workplace wellbeing. In addition, the company offers electronic questionnaires and scales, a digital bespoke questionnaire; NeuroVocalix, a voice analysis platform to analyze voice to assess neurological change; cognition kit, a high frequency testing kit to detect changes over time and day-to-day cognition with short regular tests using patients' own devices. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.

COG Price History

COG Stock News Headlines

September 26, 2023 | lse.co.uk
Cambridge Cognition swings to interim loss amid ballooning costs
September 26, 2023 | marketwatch.com
Cambridge Cognition Shares Fall on Swing to Pretax Loss; Secures GBP3 Mln Loan
September 26, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
September 25, 2023 | msn.com
Why Gouda is good for you – healthy cheeses and the ones to avoid
September 25, 2023 | mirror.co.uk
Early childhood reading brings 'lifelong rewards' and is tied to better mental health
September 25, 2023 | msn.com
Experts: Shawn Fain's biting style is creating a moment, just like another UAW labor icon
September 25, 2023 | markets.businessinsider.com
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
September 22, 2023 | msn.com
Psychotherapists Flip Freudian Thinking on Treating Depression
September 26, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
September 22, 2023 | msn.com
Suppressing negative thoughts may actually be a good thing
September 22, 2023 | americanbankingnews.com
Cambridge Cognition (LON:COG) Share Price Passes Below Two Hundred Day Moving Average of $98.74
September 21, 2023 | msn.com
Having negative thoughts? Here’s how to suppress them to improve mental health
September 20, 2023 | msn.com
Suppressing negative emotions may actually benefit your mental heath, study finds
September 20, 2023 | msn.com
Suppressing negative thoughts may be good for mental health, study suggests
September 20, 2023 | msn.com
A stiff upper lip could make you happier
September 20, 2023 | msn.com
Scientists Dispute Depression Theory on Suppressing Negative Thoughts
September 20, 2023 | msn.com
Don't let it out? Suppressing negative thoughts is good for your mental health
September 20, 2023 | msn.com
Thermo Fisher just opened a $180 million plant. Executives already are talking about expanding.
September 19, 2023 | msn.com
Best magnesium supplements to boost your overall health in 2023
September 19, 2023 | theguardian.com
Justice for Neanderthals! What the debate about our long-dead cousins reveals about us
September 15, 2023 | msn.com
7 healthy lifestyle changes that could help reduce risk of depression, says study: ‘Enormous benefits’
September 15, 2023 | bizjournals.com
Sage Therapeutics to lose 95 employees in Cambridge in mass layoff
September 14, 2023 | theguardian.com
The Guardian view on class in Britain: the government doesn’t want to talk about it
September 13, 2023 | msn.com
7 lifestyle factors that reduce the risk of depression, according to new study
September 13, 2023 | msn.com
Seven lifestyle changes that lower risk of depression
September 12, 2023 | msn.com
7 simple habits that could lower your risk of depression, even if it runs in your family
September 12, 2023 | msn.com
Healthy lifestyle ‘key for preventing depression – regardless of genetic risk’
See More Headlines
Receive COG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cambridge Cognition and its competitors with MarketBeat's FREE daily newsletter.

COG Company Calendar

Last Earnings
9/22/2020
Today
9/26/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Health Information Services
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:COG
CUSIP
N/A
CIK
N/A
Web
www.cambridgecognition.com
Phone
44 1223 810 700
Fax
N/A
Employees
80
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
56.96
P/E Growth
N/A
Net Income
N/A
Net Margins
-3.24%
Pretax Margin
N/A
Return on Equity
-112.52%
Return on Assets
-2.79%

Debt

Debt-to-Equity Ratio
18.95
Current Ratio
0.90
Quick Ratio
0.96

Sales & Book Value

Annual Sales
£12.61 million
Price / Sales
2.16
Cash Flow
GBX 18.11 per share
Price / Cash Flow
4.31
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
34,850,000
Free Float
N/A
Market Cap
£27.18 million
Optionable
Optionable
Beta
1.04
Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Matthew William Stork (Age 55)
    CEO & Director
    Comp: $342k
  • Mr. Stephen Daniel Symonds (Age 48)
    CFO & Exec. Director
    Comp: $203.31k
  • Mr. John Hammond
    Co-Founder
  • Mr. Nick Taptiklis
    Head of Technology Strategy
  • Ms. Francesca Cormack Ph.D.
    Chief Scientist
  • Mr. Simon Merritt
    Marketing and Communications Director
  • Dr. Lisa Elizabeth Nolan Ph.D. (Age 61)
    VP Bus. Devel.
  • Ms. Nicky Ackerley
    Global HR Director
  • Prof. Trevor Robbins
    Sr. Consultant
  • Prof. Barbara Sahakian FMedSci
    FBPsS, Sr. Consultant

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













COG Stock - Frequently Asked Questions

How have COG shares performed in 2023?

Cambridge Cognition's stock was trading at GBX 114 at the beginning of 2023. Since then, COG stock has decreased by 31.6% and is now trading at GBX 78.
View the best growth stocks for 2023 here.

How were Cambridge Cognition's earnings last quarter?

Cambridge Cognition Holdings Plc (LON:COG) posted its earnings results on Tuesday, September, 22nd. The company reported ($1.50) EPS for the quarter. Cambridge Cognition had a negative net margin of 3.24% and a negative trailing twelve-month return on equity of 112.52%.

What other stocks do shareholders of Cambridge Cognition own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambridge Cognition investors own include Interserve (IRV), Alio Gold Inc. (ALO.TO) (ALO), Concepta PLC (CPT.L) (CPT), IntelGenx Technologies (IGXT), Oxford Biomedica (OXB), Syneos Health (SYNH), Travelers Companies (TRV), Amryt Pharma (AMYT) and AltynGold (ALTN).

What is Cambridge Cognition's stock symbol?

Cambridge Cognition trades on the London Stock Exchange (LON) under the ticker symbol "COG."

How do I buy shares of Cambridge Cognition?

Shares of COG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Cambridge Cognition's stock price today?

One share of COG stock can currently be purchased for approximately GBX 78.

How much money does Cambridge Cognition make?

Cambridge Cognition (LON:COG) has a market capitalization of £27.18 million and generates £12.61 million in revenue each year.

How can I contact Cambridge Cognition?

Cambridge Cognition's mailing address is Tunbridge Court Tunbridge Lane, Bottisham, CAMBRIDGE, CB25 9TU, United Kingdom. The official website for the company is www.cambridgecognition.com. The company can be reached via phone at 44 1223 810 700.

This page (LON:COG) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -